Marek Fischer

Summary

Affiliation: University Hospital
Country: Switzerland

Publications

  1. pmc Next-generation sequencing of HIV-1 RNA genomes: determination of error rates and minimizing artificial recombination
    Francesca Di Giallonardo
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland
    PLoS ONE 8:e74249. 2013
  2. doi request reprint Origin of minority drug-resistant HIV-1 variants in primary HIV-1 infection
    Karin J Metzner
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland
    J Infect Dis 208:1102-12. 2013
  3. pmc A suicide gene approach using the human pro-apoptotic protein tBid inhibits HIV-1 replication
    Peter M Huelsmann
    University of Erlangen Nuremberg, Institute of Clinical and Molecular Virology, Erlangen, Germany
    BMC Biotechnol 11:4. 2011
  4. doi request reprint Minority quasispecies of drug-resistant HIV-1 that lead to early therapy failure in treatment-naive and -adherent patients
    Karin J Metzner
    Institute of Clinical and Molecular Virology, University of Erlangen Nuremberg, Erlangen, Germany
    Clin Infect Dis 48:239-47. 2009
  5. pmc Reappearance of minority K103N HIV-1 variants after interruption of ART initiated during primary HIV-1 infection
    Karin J Metzner
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland
    PLoS ONE 6:e21734. 2011
  6. doi request reprint [Evolution and Diversity of HIV-1]
    K J Metzner
    Klinik für Infektionskrankheiten und Spitalhygiene, Universitatsspital Zurich
    Praxis (Bern 1994) 100:29-35. 2011
  7. doi request reprint Efficient suppression of minority drug-resistant HIV type 1 (HIV-1) variants present at primary HIV-1 infection by ritonavir-boosted protease inhibitor-containing antiretroviral therapy
    Karin J Metzner
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, CH 8091 Zurich, Switzerland
    J Infect Dis 201:1063-71. 2010
  8. doi request reprint Prevalence of key resistance mutations K65R, K103N, and M184V as minority HIV-1 variants in chronically HIV-1 infected, treatment-naïve patients
    Karin J Metzner
    Institute of Clinical and Molecular Virology, University of Erlangen Nuremberg, Germany
    J Clin Virol 50:156-61. 2011
  9. pmc Association between specific HIV-1 Env traits and virologic control in vivo
    Beda Joos
    University Hospital Zurich, Department of Medicine, Switzerland
    Infect Genet Evol 10:365-72. 2010
  10. pmc Complement lysis activity in autologous plasma is associated with lower viral loads during the acute phase of HIV-1 infection
    Michael Huber
    Division of Infectious Diseases, University Hospital Zurich, Zurich, Switzerland
    PLoS Med 3:e441. 2006

Collaborators

Detail Information

Publications45

  1. pmc Next-generation sequencing of HIV-1 RNA genomes: determination of error rates and minimizing artificial recombination
    Francesca Di Giallonardo
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland
    PLoS ONE 8:e74249. 2013
    ..We developed an RT-PCR procedure to generate NGS data useful for reliable haplotype reconstruction and quantification. ..
  2. doi request reprint Origin of minority drug-resistant HIV-1 variants in primary HIV-1 infection
    Karin J Metzner
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland
    J Infect Dis 208:1102-12. 2013
    ..They may result from de novo mutagenesis or transmission. To date, the latter has not been proven...
  3. pmc A suicide gene approach using the human pro-apoptotic protein tBid inhibits HIV-1 replication
    Peter M Huelsmann
    University of Erlangen Nuremberg, Institute of Clinical and Molecular Virology, Erlangen, Germany
    BMC Biotechnol 11:4. 2011
    ..We tested truncated Bid (tBid), a human pro-apoptotic protein that induces apoptosis very rapidly and efficiently, as suicide gene for gene therapy against HIV-1 infection...
  4. doi request reprint Minority quasispecies of drug-resistant HIV-1 that lead to early therapy failure in treatment-naive and -adherent patients
    Karin J Metzner
    Institute of Clinical and Molecular Virology, University of Erlangen Nuremberg, Erlangen, Germany
    Clin Infect Dis 48:239-47. 2009
    ..Therefore, we evaluated the possible role of minority quasispecies of drug-resistant human immunodeficiency virus type 1, which are undetectable at baseline by population sequencing, with regard to early virological failure...
  5. pmc Reappearance of minority K103N HIV-1 variants after interruption of ART initiated during primary HIV-1 infection
    Karin J Metzner
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland
    PLoS ONE 6:e21734. 2011
    ..These mutations are key mutations conferring drug resistance to reverse transcriptase inhibitors and they belong to the most commonly transmitted drug resistance mutations...
  6. doi request reprint [Evolution and Diversity of HIV-1]
    K J Metzner
    Klinik für Infektionskrankheiten und Spitalhygiene, Universitatsspital Zurich
    Praxis (Bern 1994) 100:29-35. 2011
    ....
  7. doi request reprint Efficient suppression of minority drug-resistant HIV type 1 (HIV-1) variants present at primary HIV-1 infection by ritonavir-boosted protease inhibitor-containing antiretroviral therapy
    Karin J Metzner
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, CH 8091 Zurich, Switzerland
    J Infect Dis 201:1063-71. 2010
    ....
  8. doi request reprint Prevalence of key resistance mutations K65R, K103N, and M184V as minority HIV-1 variants in chronically HIV-1 infected, treatment-naïve patients
    Karin J Metzner
    Institute of Clinical and Molecular Virology, University of Erlangen Nuremberg, Germany
    J Clin Virol 50:156-61. 2011
    ....
  9. pmc Association between specific HIV-1 Env traits and virologic control in vivo
    Beda Joos
    University Hospital Zurich, Department of Medicine, Switzerland
    Infect Genet Evol 10:365-72. 2010
    ..These residues in HIV gp120 might affect in vivo HIV-1 fitness either at the level of Env function or influence susceptibility to adaptive or innate immune response...
  10. pmc Complement lysis activity in autologous plasma is associated with lower viral loads during the acute phase of HIV-1 infection
    Michael Huber
    Division of Infectious Diseases, University Hospital Zurich, Zurich, Switzerland
    PLoS Med 3:e441. 2006
    ..To explore the possibility that antibody-mediated complement lysis contributes to viremia control in HIV-1 infection, we measured the activity of patient plasma in mediating complement lysis of autologous primary virus...
  11. ncbi request reprint Persistence of lamivudine-sensitive HIV-1 quasispecies in the presence of lamivudine in vitro and in vivo
    Kristina Allers
    Institute of Clinical and Moleculr Virology, University of Erlangen Nuremburg, Erlangen, Germany
    J Acquir Immune Defic Syndr 44:377-85. 2007
    ....
  12. ncbi request reprint HIV-1 p24 may persist during long-term highly active antiretroviral therapy, increases little during short treatment breaks, and its rebound after treatment stop correlates with CD4(+) T cell loss
    Jorg Schupbach
    Swiss National Center for Retroviruses, University of Zurich, Zurich, Switzerland
    J Acquir Immune Defic Syndr 40:250-6. 2005
    ..Persisting p24 despite successful HAART may reflect virus replication in reservoirs not represented by plasma viral load and has implications for the concept of therapeutic vaccination...
  13. pmc In vivo and in vitro escape from neutralizing antibodies 2G12, 2F5, and 4E10
    Amapola Manrique
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Ramistrasse 100, 8091 Zurich, Switzerland
    J Virol 81:8793-808. 2007
    ..This remarkable vulnerability of the virus to interference within the MPER calls for a further evaluation of the safety and efficacy of MPER-targeting therapeutic and vaccination strategies...
  14. pmc Early antiretroviral therapy during primary HIV-1 infection results in a transient reduction of the viral setpoint upon treatment interruption
    Viktor von Wyl
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland
    PLoS ONE 6:e27463. 2011
    ..Long-term benefits of combination antiretroviral therapy (cART) initiation during primary HIV-1 infection are debated...
  15. ncbi request reprint Attenuated and nonproductive viral transcription in the lymphatic tissue of HIV-1-infected patients receiving potent antiretroviral therapy
    Marek Fischer
    Division of Infectious Diseases and Hospital Epidemiology, Department of Medicine, University Hospital Zurich, Zurich, Switzerland
    J Infect Dis 189:273-85. 2004
    ..Thus, residual lymphoid HIV-1 RNA in patients receiving HAART indicates attenuated viral transcription in HIV-1-infected cells that lack virion production...
  16. pmc Potent human immunodeficiency virus-neutralizing and complement lysis activities of antibodies are not obligatorily linked
    Michael Huber
    Division of Infectious Diseases, University Hospital Zurich, Ramistrasse 100, 8091 Zurich, Switzerland
    J Virol 82:3834-42. 2008
    ..In summary, our data support the notion that the in vivo activities of 2G12, 2F5, and 4E10 are likely due to direct neutralization or Fc receptor-mediated mechanisms such as phagocytosis and antibody-dependent cellular cytotoxicity...
  17. pmc Low human immunodeficiency virus envelope diversity correlates with low in vitro replication capacity and predicts spontaneous control of plasma viremia after treatment interruptions
    Beda Joos
    University Hospital Zurich, Department of Medicine, Division of Infectious Diseases and Hospital Epidemiology, Ramistrasse 100, CH 8091 Zurich, Switzerland
    J Virol 79:9026-37. 2005
    ....
  18. pmc HIV rebounds from latently infected cells, rather than from continuing low-level replication
    Beda Joos
    Department of Medicine, Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, CH 8091 Zurich, Switzerland
    Proc Natl Acad Sci U S A 105:16725-30. 2008
    ..Furthermore, a prolonged delay in restoration of pretreatment viral diversity after treatment interruption demonstrates a surprisingly sustained evolutionary bottleneck induced by punctuated antiretroviral therapy...
  19. ncbi request reprint Positive in vivo selection of the HIV-1 envelope protein gp120 occurs at surface-exposed regions
    Beda Joos
    Department of Medicine, Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, CH 8091, Switzerland
    J Infect Dis 196:313-20. 2007
    ....
  20. pmc Productive human immunodeficiency virus type 1 infection in peripheral blood predominantly takes place in CD4/CD8 double-negative T lymphocytes
    Philipp Kaiser
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zürich Rämistrasse, 100 8091 Zürich, Switzerland
    J Virol 81:9693-706. 2007
    ....
  21. doi request reprint Effect of early antiretroviral therapy during primary HIV-1 infection on cell-associated HIV-1 DNA and plasma HIV-1 RNA
    Sara Gianella
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland
    Antivir Ther 16:535-45. 2011
    ..Early initiation of combination antiretroviral therapy (ART) during primary HIV-1 infection may prevent the establishment of large viral reservoirs, possibly resulting in improved control of plasma viraemia rebound after ART cessation...
  22. ncbi request reprint Equal amounts of intracellular and virion-enclosed hepatitis C virus RNA are associated with peripheral-blood mononuclear cells in vivo
    Philipp Kaiser
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, 8032 Zurich, Switzerland
    J Infect Dis 194:1713-23. 2006
    ..Quantitation of HCV RNA with regard to its subcellular distribution and longitudinal course is needed for better understanding of the largely unexplored in vivo dynamics and potential pathogenetic significance of HCV in PBMCs...
  23. pmc Profound depletion of HIV-1 transcription in patients initiating antiretroviral therapy during acute infection
    Adrian Schmid
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland
    PLoS ONE 5:e13310. 2010
    ..In the current study, HIV-1 RNA transcription patterns in peripheral blood mononuclear cells (PBMC) were monitored during acute cART to assess the effect of early treatment on cellular viral reservoirs...
  24. ncbi request reprint Quantification of infectious HIV-1 plasma viral load using a boosted in vitro infection protocol
    Peter Rusert
    Division of Infectious Diseases, University Hospital Zurich, Switzerland
    Virology 326:113-29. 2004
    ..Measuring viral infectivity may thereby function as an additional, useful marker in monitoring disease progression and evaluating efficacy of antivirals in vivo...
  25. pmc Biphasic decay kinetics suggest progressive slowing in turnover of latently HIV-1 infected cells during antiretroviral therapy
    Marek Fischer
    University Hospital Zurich, Division of Infectious Diseases, Ramistrasse 100, 8092 Zurich, Switzerland
    Retrovirology 5:107. 2008
    ..These cells persisted during cART. Nevertheless, during the first four weeks of therapy their kinetics resembled that of productively infected cells...
  26. pmc CD4-specific designed ankyrin repeat proteins are novel potent HIV entry inhibitors with unique characteristics
    Andreas Schweizer
    Division of Infectious Diseases, University Hospital Zurich, Zurich, Switzerland
    PLoS Pathog 4:e1000109. 2008
    ....
  27. doi request reprint HIV-1 transmission after cessation of early antiretroviral therapy among men having sex with men
    Philip Rieder
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland
    AIDS 24:1177-83. 2010
    ..To study transmission dynamics during acute infection, during the aviremic phase over the period of early antiretroviral therapy (ART) and during the phase of viral rebound after early treatment was stopped...
  28. pmc Virus isolates during acute and chronic human immunodeficiency virus type 1 infection show distinct patterns of sensitivity to entry inhibitors
    Peter Rusert
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Ramistrasse 100, 8091 Zurich, Switzerland
    J Virol 79:8454-69. 2005
    ..Activities of these MAbs correlated significantly with each other, suggesting that common features of the viral envelope modulate their potencies...
  29. ncbi request reprint Shifts in cell-associated HIV-1 RNA but not in episomal HIV-1 DNA correlate with new cycles of HIV-1 infection in vivo
    Marek Fischer
    Division of Infectious Diseases and Hospital Epidemiology, Department of Medicine, University Hospital Zurich, 8091 Zurich, Switzerland
    Antivir Ther 8:97-104. 2003
    ..In contrast, expression of HIV-UsRNAPBMC increased during STI and consequently provides a more sensitive, albeit not absolute cellular marker of ongoing HIV-1 replication...
  30. ncbi request reprint Cellular viral rebound after cessation of potent antiretroviral therapy predicted by levels of multiply spliced HIV-1 RNA encoding nef
    Marek Fischer
    Division of Infectious Diseases and Hospital Epidemiology, Department of Medicine, University Hospital Zurich, CH 8091 Zurich, Switzerland
    J Infect Dis 190:1979-88. 2004
    ....
  31. pmc Long-term multiple-dose pharmacokinetics of human monoclonal antibodies (MAbs) against human immunodeficiency virus type 1 envelope gp120 (MAb 2G12) and gp41 (MAbs 4E10 and 2F5)
    Beda Joos
    University Hospital Zurich, Infectious Diseases and Hospital Epidemiology, Ramistrasse 100, CH 8091 Zurich, Switzerland
    Antimicrob Agents Chemother 50:1773-9. 2006
    ..Further studies examining tissue concentrations to explain the differential in vivo activity of the anti-gp120 antibody compared with those of the two anti-gp41 antibodies are warranted...
  32. ncbi request reprint Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies
    Alexandra Trkola
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Ramistrasse 100, 8091 Zurich, Switzerland
    Nat Med 11:615-22. 2005
    ....
  33. ncbi request reprint Residual cell-associated unspliced HIV-1 RNA in peripheral blood of patients on potent antiretroviral therapy represents intracellular transcripts
    Marek Fischer
    Department of Medicine, University Hospital Zurich, Switzerland
    Antivir Ther 7:91-103. 2002
    ..As shown by limiting dilution analysis, HIV-1 infected cells with such a repressed viral transcription pattern were observed at high frequencies in PBMC from untreated patients...
  34. doi request reprint Rational design of HIV-1 fluorescent hydrolysis probes considering phylogenetic variation and probe performance
    Claudia F Althaus
    Division of Infectious Diseases, University Hospital Zurich, University of Zurich, Zurich, Switzerland
    J Virol Methods 165:151-60. 2010
    ..Thus, empirically validated novel principles of FH-probe design regarding conservation and qPCR-performance were identified, which complement and extend current rules for FH-probe design...
  35. ncbi request reprint HIV-1 p24 antigen is a significant inverse correlate of CD4 T-cell change in patients with suppressed viremia under long-term antiretroviral therapy
    Jorg Schupbach
    Swiss National Center for Retroviruses, University of Zurich, Zurich, Switzerland
    J Acquir Immune Defic Syndr 33:292-9. 2003
    ..Comparison of p24 antigen and HIV-1 RNA concentrations indicate that the p24 antigen detected in these samples is not associated with viral RNA-containing particles and may originate from other compartments of virus expression...
  36. pmc Tailored enrichment strategy detects low abundant small noncoding RNAs in HIV-1 infected cells
    Claudia F Althaus
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Ramistrasse 100, CH 8091 Zurich, Switzerland
    Retrovirology 9:27. 2012
    ..Thus, we applied a novel, sequence targeted enrichment strategy to capture HIV-1 derived sncRNAs in HIV-1 infected primary CD4+ T-lymphocytes and macrophages that allows a greater than 100-fold enrichment of low abundant sncRNAs...
  37. ncbi request reprint Rapid selection of drug-resistant HIV-1 during the first months of suppressive ART in treatment-naive patients
    Karin J Metzner
    University of Erlangen Nuremberg, Institute of Clinical and Molecular Virology, Erlangen, Germany
    AIDS 21:703-11. 2007
    ..In this study, we wanted to determine whether drug-resistant viruses are already selected during viral decline within the first months of ART...
  38. ncbi request reprint A randomized trial of simplified maintenance therapy with abacavir, lamivudine, and zidovudine in human immunodeficiency virus infection
    Milos Opravil
    Division of Infectious Diseases, University Hospital, CH 8091 Zurich, Switzerland
    J Infect Dis 185:1251-60. 2002
    ....
  39. ncbi request reprint Anti-HIV-1 activity of leflunomide: a comparison with mycophenolic acid and hydroxyurea
    Erika Schläpfer
    Division of Infectious Diseases and Hospital Epidemiology, Department of Internal Medicine, University Hospital of Zurich, Switzerland
    AIDS 17:1613-20. 2003
    ..Leflunomide inhibits de novo pyrimidine synthesis by inhibiting the activity of dihydroorotic acid dehydrogenase and has other immunomodulatory properties that make it a promising candidate for an anti-HIV drug...
  40. doi request reprint The antiretroviral potency of emtricitabine is approximately 3-fold higher compared to lamivudine in dual human immunodeficiency virus type 1 infection/competition experiments in vitro
    Daniel Drogan
    University of Erlangen Nuremberg, Institute of Clinical and Molecular Virology, Erlangen, Germany
    Antiviral Res 86:312-5. 2010
    ..Mathematical modeling of the distinct rates of suppression of drug-sensitive viruses revealed an approximately 3-fold higher antiretroviral potency for FTC compared to 3TC...
  41. ncbi request reprint RANTES (CCL5) uses the proteoglycan CD44 as an auxiliary receptor to mediate cellular activation signals and HIV-1 enhancement
    Branka Roscic-Mrkic
    Division of Infectious Diseases, Department of Medicine, University Hospital, Zurich, Switzerland
    Blood 102:1169-77. 2003
    ..Here we show that silencing of CD44 in HeLa-CD4 cells prevents the activation of p44/p42 MAPK and leads to a substantial reduction in HIV-1 infectivity enhancement by RANTES...
  42. ncbi request reprint Detection of minor populations of drug-resistant HIV-1 in acute seroconverters
    Karin J Metzner
    University of Erlangen Nuremberg, Institute of Clinical and Molecular Virology, Germany
    AIDS 19:1819-25. 2005
    ..As minor populations of drug-resistant HIV-1 could impact the efficiency of antiretroviral therapy, this study was performed to determine the prevalence of minor populations of drug-resistant HIV-1 in acute seroconverters...
  43. ncbi request reprint Detection and significance of minority quasispecies of drug-resistant HIV-1
    Karin J Metzner
    Institute of Clinical and Molecular Virology, University of Erlangen Nuremberg, Schlossgarten, Erlangen, Germany
    J HIV Ther 11:74-81. 2006
  44. ncbi request reprint Inhibition of drug-resistant HIV-1 by RNA interference
    Peter M Huelsmann
    University of Erlangen Nuremberg, Institute of Clinical and Molecular Virology, Schlossgarten 4, D 91054 Erlangen, Germany
    Antiviral Res 69:1-8. 2006
    ..Taken together, these results demonstrate that RNA interference might be useful in the treatment of drug-resistant HIV-1 infection...
  45. doi request reprint Generation of HIV-1-specific T cells by electroporation of T-cell receptor RNA
    Christian Hofmann
    Department of Dermatology, University Hospital Erlangen, Erlangen, Germany
    AIDS 22:1577-82. 2008
    ..Antigen-specific cytotoxic T lymphocytes can be generated by T-cell receptor transfer. This is commonly done by retroviral transduction, which is complicated and poses the threat of stable genetic alteration of autologous cells...